Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects (Q35827758)

10 August 2017

Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects (English)

1 reference

10 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Mikko Neuvonen

3

0 references

Janne Backman

object named as

Janne T Backman

1

0 references

Pertti J. Neuvonen

object named as

Pertti J Neuvonen

5

0 references

author name string

Marjo J Karjalainen

2

1 reference

10 August 2017

Jouko Laitila

4

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

British Journal of Clinical Pharmacology

10 August 2017

1 reference

10 August 2017

62

1 reference

10 August 2017

3

1 reference

10 August 2017

345-357

1 reference

Assessment of CYP1A2 activity in clinical practice: why, how, and when?

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

Failing the public health--rofecoxib, Merck, and the FDA.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

Determination of rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

Simple high-performance liquid chromatography method for the simultaneous determination of serum caffeine and paraxanthine following rapid sample preparation.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

Clinical pharmacokinetics of tacrine.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

Pencil and paper tests-sensitivity to psychotropic drugs

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

Clinical pharmacokinetics of ciprofloxacin

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects

27 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

An Evaluation of the Dose‐Dependent Inhibition of CYP1A2 by Rofecoxib Using Theophylline as a CYP1A2 Probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

Metabolism of rofecoxib in vitro using human liver subcellular fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885136

A rapid HPLC method for monitoring plasma levels of caffeine and theophylline using solid phase extraction columns

24 September 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

The use of analogue scales in rating subjective feelings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02653.X

Biological fate of sirdalud in animals and man

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16934051

12 December 2020

inferred from PubMed ID database lookup

Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16934051

12 December 2020

inferred from PubMed ID database lookup

The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16934051

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1111/J.1365-2125.2006.02653.X

1 reference

release_ufksoh3bx5hgzms2ern6k2wxke

10 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ufksoh3bx5hgzms2ern6k2wxke

24 November 2022

mapped directly with Wikidata item

1 reference

10 August 2017

1 reference